Table 1

Summary of clinical trials evaluating kidney outcomes with SGLT2 inhibition

StudyInterventionInclusion criteriaMain kidney outcomes
EMPA-REG OUTCOME (NCT01131676) (34,36)Empagliflozin vs. placebo• T2D
• High CVD risk
• eGFR >30 mL/min/1.73 m2• 39% relative risk reduction for incident or worsening nephropathy (12.7% vs. 18.8%)
• 38% relative risk reduction for progression to albuminuria (11.2% vs. 16.2%)
• 44% relative risk reduction of doubling of serum creatinine (1.5% vs. 2.6%)
• 55% relative risk reduction of need for initiation of KRT (0.3% vs. 0.6%)
CANVAS Program (NCT01032629, NCT01989754) (38)Canagliflozin vs. placebo• T2D
• High CVD risk
• Mean eGFR of 76.5 mL/min/1.73 m2• Decreased progression of albuminuria (hazard ratio 0.73; 95% CI 0.67–0.79)
• Decrease in composite outcome of a sustained 40% reduction in eGFR, KRT, or death from kidney causes (hazard ratio 0.60; 95% CI 0.47–0.77)
DECLARE-TIMI 
58 (NCT01730534) (40)Dapagliflozin vs. placebo• T2D
• High CVD risk
• eGFR ≥60 mL/min/1.73 m2Results pending:
• Kidney composite end point (sustained ≥40% decrease in eGFR to eGFR <60 mL/min/1.73 m2 and/or ESKD and/or renal or CVD death)
VERTIS CV (NCT01986881) (90)Ertugliflozin vs. placebo• T2D 
• History of atherosclerosis of the coronary, cerebral, or peripheral vascular systemsResults pending:
• Kidney composite end point (kidney death, KRT, or doubling of serum creatinine)
CREDENCE (NCT02065791) (41)Canagliflozin vs. placebo• T2D 
• eGFR ≥30 to <90 mL/min/1.73 m2
• UACR >300 to ≤5,000 mg/g
• Stabilization on maximum labeled or tolerated dose of an ACE inhibitor or angiotensin II receptor blockerResults pending:
• Kidney composite end point (ESKD, doubling of serum creatinine, and kidney or CVD death)
• Change in eGFR over time
• Change in albuminuria over time
Dapa-CKD (NCT03036150) (87)Dapagliflozin vs. placebo• T2D with DKD and nondiabetic kidney disease
• eGFR ≥25 to ≤75 mL/min/1.73 m2
• UACR ≥200 to ≤5,000 mg/g
• Stabilization on maximum labeled
or tolerated dose of an ACE inhibitor or
angiotensin II receptor blocker (unless contraindicated)Results pending:
• Kidney composite end point (≥ 50% sustained decline in eGFR, ESKD, or kidney or CVD death)
• Change in eGFR over time
• Change in albuminuria over time
EMPA-KIDNEY
(NCT03594110)
(91)Empagliflozin
vs. placebo• eGFR ≥20 to <45 mL/min/1.73 m2
OR eGFR ≥45 to <90 mL/min/1.73 m2 with UACR ≥200 mg/g
• Clinically appropriate dose of an ACE inhibitor or angiotensin II receptor blocker unless not tolerated or indicatedResults pending:
• Composite outcome of time to first occurrence of:
• Kidney disease progression (ESKD, sustained decline in eGFR to <10 mL/min/1.73 m2, kidney death, or a
sustained decline of ≥40% in eGFR from randomization), OR
• Cardiovascular death
  • DECLARE-TIMI 58, Dapagliflozin Effect on Cardiovascular Events trial.